Treatment of Parkinson’s patients (PD) with nilotinib, 150 mg or 300 mg, results in maximum cerebrospinal fluid (CSF) concentration (Cmax) of 1.9 nM and 4.12 nM, respectively, and a dose-dependent increase in DA levels [21,22,23]; achieving a pharmacologically adequate concentration that would inhibit DDR1. Here, DDR1 is linked to Parkinson disease.